Skip to main content
R

R&G PharmaStudies Co., Ltd. — Investor Relations & Filings

Ticker · 301333 Shenzhen Stock Exchange Professional, scientific and technical activities
Filings indexed 475 across all filing types
Latest filing 2026-04-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301333

About R&G PharmaStudies Co., Ltd.

https://www.rg-pharma.com

R&G PharmaStudies Co., Ltd. is a comprehensive Contract Research Organization (CRO) providing full-service clinical research solutions to the global pharmaceutical and biotechnology sectors. The company specializes in managing Phase I through IV clinical trials, offering a broad suite of services including clinical trial operation, site management, medical writing, regulatory affairs, and pharmacovigilance. Additionally, R&G provides specialized expertise in data management and biostatistics, ensuring high-quality data integrity and compliance with international standards such as NMPA, FDA, and EMA. With an extensive network of clinical trial sites and a focus on diverse therapeutic areas, the company facilitates efficient drug development processes. R&G is recognized for its integrated approach to clinical development, supporting clients from early-stage research through to post-marketing surveillance and bioequivalence studies.

Recent filings

Filing Released Lang Actions
2026年一季度报告
Regulatory Filings
2026-04-27 Chinese
第五届董事会第二十次会议决议公告
Regulatory Filings Classification · 1% confidence The document is an announcement of the board of directors’ resolutions from the company’s fifth board meeting, including approval of the Q1 report and voting tallies by directors. It is not the Q1 report itself (no financial statements included) nor an AGM or shareholder vote, nor changes in board composition. It does not fit any specialized category and serves as a general regulatory announcement of a board meeting outcome. Therefore it is classified as a Regulatory Filing (RNS).
2026-04-27 Chinese
关于持股5%以上股东及特定股东减持股份触及1%的整数倍暨减持计划提前实施完成的公告
Regulatory Filings
2026-04-21 Chinese
中国国际金融股份有限公司关于诺思格(北京)医药科技股份有限公司2025年度持续督导跟踪报告
Regulatory Filings
2026-04-14 Chinese
中国国际金融股份有限公司关于诺思格(北京)医药科技股份有限公司持续督导保荐总结报告书
Regulatory Filings
2026-04-10 Chinese
简式权益变动报告书
Regulatory Filings
2026-04-03 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.